Morgan Stanley lowered the firm’s price target on Nucor (NUE) to $166 from $170 and keeps an Overweight rating on the shares. The firm is updating estimates following Q3 earnings to include the company Q4 guidance and commentary.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NUE:
- Closing Bell Movers: Medpace down 11% after cutting FY24 revenue guide
- NUE Earnings: Nucor Slides after Q3 EPS Misses Estimates
- Nucor’s Q3 Earnings Drop but Strategic Growth Persists
- Nucor reports Q3 adjusted EPS $1.49, consensus $1.47
- Nucor expects earnings in Q4 to decrease compared to Q3 EPS of $1.05